Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2015 ASCO Annual Meeting /
Cobimetinib plus vemurafenib for advanced BRAF-mutated melanoma

29th May - 2nd Jun 2015

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.06.15
Views: 3626

Dr James Larkin - Royal Marsden Hospital, London, UK

Dr Larkin talks to ecancertv at ASCO 2015 about an update on a phase III study of cobimetinib plus vemurafenib in advanced BRAF-mutated melanoma: Progression-free survival and correlative biomarker analysis from the coBRIM trial.

Longer follow-up has confirmed the clinical benefit of vemurafenib and cobimetinib in patients with advanced BRAF V600-mutated melanoma.

Co-existence of BRAF V600 and baseline activating RAS/RAF/RTK mutations do not seem to affect disease progression or rate of response to the treatment. 

Read the news article for more.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation